2020
DOI: 10.21518/2079-701x-2020-20-143-149
|View full text |Cite
|
Sign up to set email alerts
|

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer

Abstract: Introduction. The presence of a germinal BRCA mutation occurs in 3–4% of all breast cancer (BC) patients with various biological subtypes, but significantly with a high frequency in patients with a triple negative biological subtype (in 10–20% of cases). For the treatment of patients with HER2-negative metastatic breast cancer associated with gBRCA mutation, the effectiveness of biologically targeted drugs from the group of PARP inhibitors (olaparib and talazoparib) has been proven.Purpose. Comparison of the r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(5 citation statements)
references
References 8 publications
0
5
0
Order By: Relevance
“…This study was the first real-world evaluation conducted in the USA. However, similar studies have been conducted in France, 14 Turkey, 15 and Russia 16 and have been published.…”
Section: Discussionmentioning
confidence: 53%
See 4 more Smart Citations
“…This study was the first real-world evaluation conducted in the USA. However, similar studies have been conducted in France, 14 Turkey, 15 and Russia 16 and have been published.…”
Section: Discussionmentioning
confidence: 53%
“…It should also be noted that patients in the Turkish and Russian studies were heavily pretreated and initiated talazoparib in later lines of therapy (3 or more lines of therapy were received prior to talazoparib among 10.7%, 51.5%, and 33.5% in the real-world studies set in the USA, Turkey, and Russia, respectively). 15 , 16 The median rwPFS for talazoparib was 8.7 months (median follow-up period of 8.2 months) for the US study population and 6.5 months (median follow-up time of 13.6 months) for the Turkish BRCA -mutated breast cancer patient study population. 15 In addition, rwORR for talazoparib was 63.1% for the US study population versus 31.9% for the Turkish study population.…”
Section: Discussionmentioning
confidence: 97%
See 3 more Smart Citations